Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 4—April 2025
Synopsis

Maternal and Fetal Implications of Oropouche Fever, Espírito Santo State, Brazil, 2024

João Paulo Cola1, Ana Paula Brioschi dos Santos1, Raphael Lubiana Zanotti, Adriana Endlich da Silva Dela Costa, Karina Bertazo Del Carro, Lesliane de Amorim Lacerda Coelho, Angelica Espinosa Miranda2, and Creuza Rachel Vicente2Comments to Author 
Author affiliation: Secretaria de Estado da Saúde do Espírito Santo, Vitória, Brazil (J.P. Cola, A.P. Brioschi dos Santos, R. Lubiana Zanotti, A. Endlich da Silva Dela Costa, K. Bertazo Del Carro, L. de Amorim Lacerda Coelho); Universidade Federal do Espírito Santo, Programa de Pós-Graduação em Doenças Infecciosas, Vitória, Brazil (A.E. Miranda, C.R. Vicente)

Main Article

Table 1

Demographic and clinical characteristics of 73 pregnant women with Oropouche virus infection in Espírito Santo State, Brazil, March 28–December 22, 2024*

Characteristic Pregnancy ongoing, n = 58 Pregnancy concluded, n = 15 Total
Age, y
Median (IQR) 29 (24–34) 28 (25–31) 29 (24–33)
Mean (+SD) 28.70 (5.73) 28.73 (4.84) 28.71 (5.52)
18–19 4 (6.90) 0 4 (5.48)
20–29 26 (44.83) 9 (60.00) 35 (47.95)
30–39 27 (46.55) 5 (33.33) 32 (43.84)
40–42
1 (1.72)
1 (6.67)
2 (2.74)
Underlying condition
Hypertension 6 (10.34) NA 6 (8.22)
Diabetes
1 (1.72)
NA
1 (1.37)
Pregnancy trimester during Oropouche fever
First 12 (20.69) 2 (13.33) 14 (19.18)
Second 26 (44.83) NA 26 (35.62)
Third
20 (34.48)
13 (86.67)
33 (45.21)
Oropouche fever clinical manifestation
Fever 42 (72.41) 13 (86.67) 55 (75.34)
Headache 46 (79.31) 13 (86.67) 59 (80.82)
Myalgia 41 (70.69) 11 (73.33) 52 (71.23)
Back pain 23 (39.66) 5 (33.33) 28 (38.36)
Arthralgia 8 (13.79) 2 (13.33) 10 (13.70)
Retro-ocular pain 27 (46.55) 5 (33.33) 32 (43.84)
Nausea 23 (39.66) 6 (40.00) 29 (39.73)
Vomiting 11 (18.97) NA 11 (15.07)
Petechia 4 (6.90) 1 (6.67) 5 (6.85)
Exanthema 9 (15.52) 2 (13.33) 11 (15.07)

*Values are no. (%) except as indicated. IQR, interquartile range; NA, not applicable.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: February 05, 2025
Page updated: February 24, 2025
Page reviewed: February 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external